Consent from new patient at first registration

Just as the patient can take a proper decision only if full information is available to him/her, the doctor can take the most appropriate decision for a patient only if the patient provides full and up-to-date information. Unfortunately this does not happen all the time. The Ministry of Health and Family Welfare recommends the Charter of Patients Rights which also includes a specific section on responsibilities of patients and their family members. Based on the legal principle that consent is a contract between two parties, we followed a systematic procedure to develop consensus recommendation for obtaining patient consent in the normal practice setting at first registration/ presentation.

A Review On Herbo Mineral Formulations Containing Lauha (iron) W.s.r To Rasendra Sara Sanghraha

Rasendra Sara Sangraha is the oldest and most exhaustive treatise of Rasa Shastra, an important branch of Ayurveda, which revolutionised Ayurveda Pharmacopeia in the medieval period. It is one of classical works of 14th century period written by Sri Gopala Krishna Bhatt consists of 5 chapters with 2531 verses. Rasendra Sara Sangraha comprising the compilation of various times tested and therapeutically proved Rasayoga formulations. Lauha (iron) is a very essential element of the body system for treating many disease conditions as well as for physiological existence. Iron used as medicine from the Vedic period. Lauha preparations are extensively used from Acharya Charaka’s period in the form of Ayasruti and Navayasa loha. Rasendra Sara Sangraha has mentioned a total of 222 herbo mineral formulations having Lauha (iron). The present study deals with the chapter wise review of formulations of Rasendra Sara Sangraha containing Lauha as an ingredient mentioned in various disease conditions like Jwara, Arsas, krimi, Pandu, Soola, Pradara, Sodha and Gulma etc. These Lauha containing Herbo mineral Formulations has been elaborately compiled in 222 formulations.

Screening of C-kit gene mutation in acute myeloid leukaemia in northern India

Acute Myeloid Leukaemia [AML] is a cancer of blood-forming cells in bone marrow. C-kit gene is a Receptor Tyrosine Kinase class III [RTK] that is expressed by early hematopoietic progenitor cells and plays an important role in hematopoietic stem cell proliferation, differentiation and survival. It is known that c-kit is a proto-oncogene and the activating c-kit mutations are likely to contribute in the development of leukaemia in humans. Exon 11 of c-Kit gene is the frequent site for mutations in different kinds of tumours. In order to determine the frequency and prevalence of exon 11 mutations in 51 AML cases, we have done polymerase chain reaction-single-strand conformational polymorphism followed by direct DNA sequencing. The c-kit mutations in exon 11 were detected in 15.68% [8/51] in AML cases. We have detected totally ten missense mutations in eight AML cases those include Lys550Asn, Tyr568Ser, Ile571Leu, Tyr578Pro, Trp582Ser and Arg588Met and novel missense mutations at codons Ile563Lys and Val569Leu. Mutations at codons Ile571Leu and Trp582Ser was found in two independent cases. The presence of c-kit mutations in our study adds to investigative spectrum of AML cases. Since the c-kit mutations are seen in other malignancies, mutations in exon 11 of the c-kit gene might be involve in pathogenesis and represent useful predictive genetic marker in AML. Further studies in larger group of cases possibly will be required to determine the prognostic implications and to investigate how these mutations are co-related to the progression and pathogenesis of AML